One in eight adults in the U.S. has taken Ozempic or another type of GLP-1 drug, surveys show — and now a major new study has revealed a long list of benefits and some little-known risks.

The Food and Drug Administration approved Ozempic for treating patients with chronic kidney disease on Tuesday, marking the latest authorized use for Novo Nordisk’s popular drug known for ...

By Dani Blum The Food and Drug Administration on Tuesday approved Ozempic to reduce the risk of serious complications in people who have both Type 2 diabetes and chronic kidney disease.

Yet another study is supporting the notion that the blockbuster GLP-1 drug Ozempic can help problems drinkers curb their intake. The research found that, compared to placebo, weekly injections of ...